Biohemijska uloga homocisteina u imunoj modulaciji i dinamici citokina u akutnom ishemijskom moždanom udaru: implikacije za infekcije povezane sa moždanim udarom

Biochemical Analysis of Cytokine Dynamics in Acute Ischemic Stroke

  • Jiayi Cai Department of Rehabilitation, Shanghai Putuo District Central Hospital
  • Qiuxin Xu Department of Rehabilitation, Shanghai Putuo District Central Hospital
  • Haofeng Shen Shanghai Shengxi Rehabilitation Center
DOI: https://doi.org/10.5937/jomb0-56695

Sažetak


Background: Ischemic stroke is a leading cause of morbidity and mortality, with immune dysregulation contributing to its progression. Elevated homocysteine (Hcy) levels are implicated in altering immune responses and increasing stroke severity. This study aimed to investigate the biochemical role of serum homocysteine in modulating immune responses, particularly cytokine profiles, and its association with post-stroke infections in patients with acute ischemic stroke.
Methods: A cohort of 106 patients with acute ischemic stroke was divided into Low-, Medium-, and High-Hcy groups. Serum levels of cytokines (IL-6, IL-4, IFN-γ, IL-10) and immune modulation markers (e.g., IFN-γ/IL-4 ratio) were quantified. The presence of stroke-associated infections (SAI) was recorded, and its relationship with immune parameters was analyzed.
Results: The High-Hcy group showed significantly higher serum levels of IL-6, IFN-γ, and IL-10 compared to the Low-Hcy group (P < 0.05), suggesting a pro-inflammatory bias. In patients with SAI, IL-4 levels were notably elevated, and the IFN-γ/IL-4 ratio indicated an immune suppressive trend. Although stroke severity was similar across groups, those with heightened immune dysregulation were more prone to infections.
Conclusions: Elevated homocysteine levels induce a shift in immune responses by promoting pro-inflammatory cytokines while influencing anti-inflammatory pathways. This immune modulation is associated with an increased risk of post-stroke infections, emphasizing the dual role of cytokine dynamics in stroke pathophysiology. Targeting these biochemical pathways may present novel therapeutic strategies to mitigate stroke complications.

Reference

1. Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet 2024; 403(10446): 2820-36.
2. Xu W, Guo Y, Zhao L, Fu R, Qin X, Zhang Y, et al. The Aging Immune System: A Critical Attack on Ischemic Stroke. Mol Neurobiol 2025; 62(3): 3322-42.
3. Shi GS, Qin QL, Huang C, Li ZR, Wang ZH, Wang YY, et al. The Pathological Mechanism of Neuronal Autophagy-Lysosome Dysfunction After Ischemic Stroke. Cell Mol Neurobiol 2023; 43(7): 3251-63.
4. Kamel H, Navi BB, Merkler AE, Baradaran H, Diaz I, Parikh NS, et al. Reclassification of Ischemic Stroke Etiological Subtypes on the Basis of High-Risk Nonstenosing Carotid Plaque. Stroke 2020; 51(2): 504-10.
5. Sun X, Gao J, Meng X, Lu X, Zhang L, Chen R. Polarized Macrophages in Periodontitis: Characteristics, Function, and Molecular Signaling. Front Immunol 2021; 12: 763334.
6. Zheng Y, Ren Z, Liu Y, Yan J, Chen C, He Y, et al. T cell interactions with microglia in immune-inflammatory processes of ischemic stroke. Neural Regen Res 2025; 20(5): 1277-92.
7. Alsbrook DL, Di Napoli M, Bhatia K, Biller J, Andalib S, Hinduja A, et al. Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke. Curr Neurol Neurosci 2023; 23(8): 407-31.
8. Pawluk H, Wozniak A, Grzesk G, Kolodziejska R, Kozakiewicz M, Kopkowska E, et al. The Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke. Clin Interv Aging 2020; 15: 469-84.
9. Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, et al. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine 2020; 99(12): e19467.
10. Liang Y, Shi X, Chen L, Li Y, Zhong J. Homocysteine level at the acute stage of ischemic stroke as a biomarker of poststroke depression: A systematic review and meta-analysis. Front Psychiatry 2022; 13: 1016700.
11. Rabelo NN, Telles J, Pipek LZ, Farias VNR, Gusmao RC, Teixeira MJ, et al. Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis. Plos One 2022; 17(10): e0276087.
12. Alemseged F, Rocco A, Arba F, Schwabova JP, Wu T, Cavicchia L, et al. Posterior National Institutes of Health Stroke Scale Improves Prognostic Accuracy in Posterior Circulation Stroke. Stroke 2022; 53(4): 1247-55.
13. El HN, Katzan IL, Rost NS, Blake ML, Byun E, Pendlebury ST, et al. Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2023; 54(6): e272-91.
14. Shehjar F, Maktabi B, Rahman ZA, Bahader GA, James AW, Naqvi A, et al. Stroke: Molecular mechanisms and therapies: Update on recent developments. Neurochem Int 2023; 162: 105458.
15. Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Invest 2020; 130(6): 2777-88.
16. Brea D. Post-stroke immunosuppression: Exploring potential implications beyond infections. Eur J Neurosci 2023; 58(11): 4269-81.
17. Faura J, Bustamante A, Miro-Mur F, Montaner J. Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections. J Neuroinflamm 2021; 18(1): 127.
18. Qiao H, Xu Q, Xu Y, Zhao Y, He N, Tang J, et al. Molecular chaperones in stroke-induced immunosuppression. Neural Regen Res 2023; 18(12): 2638-44.
19. Bai M, Sun R, Cao B, Feng J, Wang J. Monocyte-related cytokines/chemokines in cerebral ischemic stroke. Cns Neurosci Ther 2023; 29(12): 3693-712.
20. Zhu H, Hu S, Li Y, Sun Y, Xiong X, Hu X, et al. Interleukins and Ischemic Stroke. Front Immunol 2022; 13: 828447.
21. Hermann A, Sitdikova G. Homocysteine: Biochemistry, Molecular Biology and Role in Disease. Biomolecules 2021; 11(5):
22. Kaplan P, Tatarkova Z, Sivonova MK, Racay P, Lehotsky J. Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems. Int J Mol Sci 2020; 21(20):
Objavljeno
2025/04/02
Broj časopisa
Vol. 44 Br. 6 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Jiayi Cai, Qiuxin Xu, Haofeng Shen

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.